Update on latest achievements - The Royal Wolverhampton ...

TCS
11
Why is this happening?
Transforming Community Services, (TCS), is a National
programme of change.
It’s been introduced to achieve greater service
integration through a structural reform of community
services provided directly by the PCTs. The reform
aims to modernize the delivery of these services.
It will do this in a number of ways by:
• Enabling and empowering staff to free their time
to care for patients
• Empowering clinicians to help shape the future of
community services
• Making services more sustainable and flexible
TCS is an aspiration of the NHS Next Stage Review and
the new White Paper: Liberating the NHS. It means
that the commissioning of health care will be designed
to promote high quality standards of care.
The Next Stage Review sets out the vision for primary
and community care. It gives people more choice
and control over their own health care and promotes
healthy lifestyles and equity for all.
Transforming
Community
Services <strong>Update</strong>
What will TCS achieve?
TCS aims to improve community services so they
can continue to provide modern, personalised and
responsive care. It also means that every Primary Care
Trust in England will no longer be a direct provider of
community care services.
What is the Trust’s Role in this?
The Trust is very proud in the way it has grown its
services and now provides secondary and tertiary care
for people across the West Midlands.
The majority of people living in Wolverhampton see
us as their local hospital and first choice for health
care. Because of our long history of working together
to improve services for people, it seemed sensible to
integrate with the provider services of WCPCT.
What have we been doing?
There are several themes we need to look at as we
prepare for integration. These are:
• Due diligence
An investigation or audit of a potential investment
• Corporate services review
How to support systems by using existing
corporate skills and workforce
• HR arrangements
Vacancy management and policies and procedures
specific to TCS
• Shadow monitoring arrangements
Services working alongside each other to prepare
for the transfer.
To help us meet the Government’s deadline of 1 April
2011, we will be introducing shadow arrangements
during the Autumn. This will see services beginning to
work alongside those within WPCT, in preparation for
the formal transfer date on 1 April 2011.
How will we keep you informed?
We will continue to keep you informed through our
internal communications.
This includes regular newsletters, your TCS intranet
page and a series of frequently asked questions, which
will be updated regularly.
If you have any queries, please send them to:
samanthaturner@nhs.net
“The Trust welcomes this opportunity to put into
practice the integrated approach to care we’ve been
developing for some time,” says Chief Executive,
David Loughton CBE.
“We work very closely with services in the WPCT
and these proposals represent a real opportunity to
further develop the care we offer to the people of
Wolverhampton and beyond. We will also ensure that
our excellent standards continue whilst the transfer
goes through.”
R&D
Developments
Last year, Research and Development achieved an
impressive £3.7 million turnover here at the Trust.
The team works closely with a number of key partners
to facilitate the advancement of knowledge, treatment,
care and modernisation through research and innovation
activity which will, ultimately, benefit our current and
future patients. Key partners include the West Midlands
Comprehensive Local Research Network, Greater
Midlands Cancer Research Network, Stroke Research
Network and Medicines for Children Research Network.
What we do
The Trust has been a very successful partner site for
leading researchers across the NHS and Industry to
validate new methods, treatments and knowledge
and our patients have been very keen to explore such
opportunities as part of their treatment planning. We
are a developing our capabilities in developing our own
research trials and this is a very exciting time for the
Trust as leading clinicians, nurses and allied healthcare
professions develop professionally and lead the way for
direct patient improvements through research.
The Directorate has also achieved credit for its
innovation management work with staffs, academia,
industry and patients. The R&D Directorate has
championed innovators to local and national recognition.
Products which have been supported, developed and
commercialised by the Trust via R&D are now being
commercially sold back into the NHS, Private healthcare,
on-line and via prescription.
In broad terms, Research and Development is dedicated
to reducing barriers to improving patient care by seeking
research and innovative opportunities which will improve
knowledge, care, treatment and choice.
“Research is incredibly important within a hospital,” says
Directorate Manager of Research and Development,
Yvonne Hague. “For some patients standard treatment
is not effective and patients will ask “what research
is available”, and it becomes more important to seek
alternative options in the hope of preventing, improving
or curing their illness”
Mouletec Cushion
The R&D Directorate work to very strict protocols and
regulations to protect the patient confidentiality and
healthcare whilst involved in a trial. Staff from across
the Trust receive specialist training to conduct or take
part in any trials.
Pioneers
The Trust has achieved several ‘firsts’ in Research and
Development as well. “We were behind the introduction
of the first patient innovation Ortho-glide. We were also
the first Trust to feature a product in the NHS catalogue
called Hook-it. This led to the Hook-on, followed by
Femmax and the Mouletec cushion and mattress.
An Orthoglide is a simple lower limb exerciser device
that aids rehabilitation after trauma or surgery to the
knees or hips.
Femmax
The Femmax is a dilator initially developed to address
the clinical risks for women who acquire vaginal
adhesions following gynaecological surgery and
radiotherapy treatment. Under clinical supervision it
has since been used for women who wish to train their
vaginal and has proved highly beneficial.
And the Mouletec technology helps even the pressure on
buttocks and upper legs. In tests, compared with other
seats, Mouletec seats not only provide extreme comfort
but also improve lower limb venous blood flow.
Who we are
R&D Director – Dr. James Cotton
R&D Directorate Manager – Mrs Yvonne Hague
Project Manager – Mrs Lorraine Jacques
Research Nurse Manager – Mrs Pauline Boyle
Business Support Manager – Mrs Kate Lees
R&D
12